Ironwood Pharmaceuticals Q2 revenue beats expectations

Ironwood Pharmaceuticals reported Q2 2025 revenue of $85.2 million, surpassing analyst expectations of $60.8 million. Adjusted EBITDA also exceeded estimates, reflecting improved operational efficiency. LINZESS U.S. net sales grew 17% year-over-year, driven by increased prescription demand. The company maintains its 2025 guidance for LINZESS net sales at $800-$850 million and anticipates total revenue between $260 million and $290 million. The average analyst rating is "hold," with a median 12-month price target of $1.00, indicating a potential upside from the current stock price of $0.81.